APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: The CML elevated plasma AST level was significantly decreased by the co-treatment of apoA-I:CIGB-258 up to 23% (p < 0.001), 25% (p < 0.001), 32% (p < 0.001), and 40% (p < 0.001) at 1:0, 1:0.1, 1:0.5, and 1:1 molar ratio, respectively.